M
Masaaki Hirobe
Researcher at University of Shizuoka
Publications - 9
Citations - 198
Masaaki Hirobe is an academic researcher from University of Shizuoka. The author has contributed to research in topics: CYP3A4 & Reductase. The author has an hindex of 4, co-authored 9 publications receiving 188 citations.
Papers
More filters
Journal ArticleDOI
Inhibition ofE. coli growth by fullerene derivatives and inhibition mechanism
Tadahiko Mashino,Kensuke Okuda,Takashi Hirota,Masaaki Hirobe,Tetsuo Nagano,Masataka Mochizuki +5 more
TL;DR: Inhibition of energy metabolism is concluded to be a mechanism of the growth inhibition effect of fullerene derivatives.
Journal Article
Novel Metabolic Pathway of Estrone and 17β-Estradiol Catalyzed by Cytochrome P-450
TL;DR: The results show that estrone and 17beta-estadiol were converted into the corresponding quinols by CYP1A1, CYB2B6, and CYP2E1.
Journal ArticleDOI
Inhibitory effect of fullerene derivatives on glutathione reductase
Tadahiko Mashino,Kensuke Okuda,Takashi Hirota,Masaaki Hirobe,Tetsuo Nagano,Masataka Mochizuki,Masataka Mochizuki,Masataka Mochizuki +7 more
TL;DR: Fullerene derivatives which have carboxylic acid moiety effectively inhibited glutathione reductase activity and enhanced the inhibition activity at 37°C.
Patent
No radical measuring method and apparatus
Tetsuo Nagano,Kazuya Kikuchi,Masaaki Hirobe,Hiroshi Hayakawa,Yasunobu Hirata,Tsuneaki Sugimoto,Higashidate Sakae +6 more
TL;DR: In this paper, a real-time NO radical measuring method was proposed, comprising the steps of mixing a test sample solution containing NO radicals with hydrogen peroxide or an analogous substance to measure the intensity of chemiluminescence.
Patent
Ethylenediamine compound-iron complex
TL;DR: The tris[2-(2-pyridylmethyl)aminoethyl]amine-iron complex of formula I or N,N,N',N'-tetrakis(2-polymethyl)-1,2-ethanediamine-iron-complex of formula II use: Useful as an active oxygen eliminating agent It is prepared in the form of drug preferably by including in a fat globule to effect the transfer of the drug to the desired cell part and eliminate the inflammation-causing active oxygen at the site.